AbbVie (ABBV) Free Cash Flow (2012 - 2026)

AbbVie (ABBV) has reported Free Cash Flow for 15 consecutive years, with $3.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 36.24% year-over-year to $3.1 billion in Q2 2026; TTM through Jun 2026 was $18.2 billion, a 0.16% change from a year earlier, with the FY2025 full-year figure at $17.8 billion, changed 0.09% from the prior year.
• Free Cash Flow was $3.1 billion for Q2 2026 at AbbVie, down from $3.6 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $7.4 billion in Q3 2022 and troughed at $1.4 billion in Q1 2025.
• A 5-year average of $4.9 billion and a median of $4.9 billion in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 66.94% in 2024 and surged 154.57% in 2026, its largest moves.
• Over 5 years, Free Cash Flow stood at $7.2 billion in 2022, then sank by 36.96% to $4.5 billion in 2023, then surged by 48.57% to $6.8 billion in 2024, then decreased by 27.65% to $4.9 billion in 2025, then tumbled by 36.31% to $3.1 billion in 2026.
• The last three Free Cash Flow figures came in at $3.1 billion (Q2 2026), $3.6 billion (Q1 2026), and $4.9 billion (Q4 2025), per Business Quant data.